Clinical trial
ARQ 197 in Subjects With Metastatic Solid Tumors
NCT00302172 · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), Industry · Completed
Key facts
| NCT number | NCT00302172 |
|---|---|
| Title | ARQ 197 in Subjects With Metastatic Solid Tumors |
| Official title | A Phase 1 Dose Escalation Study of ARQ 197 in Adult Patients With Metastatic Solid Tumors |
| Lead sponsor | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer, Tumor |
| Intervention type | Drug |
| Interventions | ARQ 197 |
| Enrollment | 78 |
| Start date | Jan 1, 2006 |
| First posted | Mar 14, 2006 |
| Last update posted | Aug 26, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: